Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth

Fig. 1

UM-UC-3 cells were treated with 0, 0.0001, 0.001, 0.01, 0.1, 1, 10, 100, or 1000 μM concentrations of niraparib, olaparib, rucaparib, talazoparib, veliparib, or cisplatin for 72 h. Cell survival was reported as % cells surviving compared with vehicle-treated control. IC50s were calculated using the AAT Bioquest Online IC50 calculator

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us